Novavax Initiates Phase 1 Clinical Trial Of RSV Vaccine Candidate In Elderly Adults

ROCKVILLE, Md., Oct. 15, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that enrollment has begun in a Phase 1 dose-ranging clinical trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adults 60 years of age and older.

This randomized, blinded, placebo-controlled Phase 1 study will evaluate the immunogenicity and safety of two doses of Novavax' RSV-F nanoparticle protein micelle vaccine candidate with and without aluminum phosphate as an adjuvant. The study is similar to the recently launched Phase 2 RSV study in women of childbearing age but will enroll 220 adults 60 years of age and older who will receive a single intramuscular injection of Novavax' RSV-F nanoparticle protein micelle vaccine or placebo plus a single dose of licensed influenza vaccine or placebo at days 0 and 28. Safety and immunogenicity will be evaluated for up to one year.

"Respiratory syncytial virus is a frequent cause of winter respiratory illnesses in the elderly and in some seasons can equal or exceed influenza's rates of disease requiring medical attention. This study extends our clinical program designed to meet this population's need for an RSV vaccine. The study will evaluate the safety and immunogenicity of our RSV vaccine candidate in elderly adults and will help us determine the optimal dosing regimen for future studies," said Gregory Glenn M.D., Senior Vice President and Chief Medical Officer of Novavax. "We expect to report top-line results from this study in the second quarter of 2013."

About RSV

RSV is a major respiratory pathogen in infants, children, and adults. RSV infections in adults represent re-infections and are generally mild to moderate in severity, except in persons with high-risk conditions including the elderly and adults with underlying chronic cardiac or pulmonary disease. It is estimated that between 11-17,000 adults die of RSV infection annually in the U.S., with and up to 180,000 admitted to hospital with respiratory symptoms. Currently, there is no approved RSV prophylactic vaccine available.

If you liked this article you might like

Biotech Movers: Novavax Falls Again After New Data on RSV Vaccine Fails to Excite

Biotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm

Biotech Movers: Alexion, Arena, Novavax

Biotech Movers: Pacific Biosciences Shares Lower After Pricing Stock Offering